Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib PK in Hepatic Impairment
NCT05216367Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of fruquintinib in metastatic colorectal cancer (mCRC) (3 arms), sponsored by HUTCHMED. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Mar 2022; status: completed.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05216367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216367.